Objectives: The use of antimicrobial drugs for food animals selects for resistant non-typhoid Salmonella strains, but human consumption of antimicrobial drugs may also increase the risk of subsequent infection. The aim of this study was to determine the risk of salmonellosis attributable to human consumption of antimicrobial drugs in a case -control study of 22602 laboratory-confirmed Salmonella infections, diagnosed in Denmark between 1997 and 2005.
Introduction
In many countries, antimicrobial drug resistance in foodborne pathogens is recognized as an increasing problem. 1 -4 The widespread use of antimicrobial drugs for food animals is the major factor for the selection and dissemination of resistance in zoonotic foodborne pathogens such as non-typhoid Salmonella enterica serotypes (hereafter named Salmonella). 5 -9 Zoonotic bacteria are usually already resistant at the time of human exposure from food sources. However, it has also been suggested that human antimicrobial drug use is an additional risk factor for antimicrobial drug resistance in foodborne pathogens. Thus, several epidemiological studies show that pre-infection antimicrobial therapy (for indications other than gastroenteritis) is a risk factor for infection with antimicrobial drug-resistant bacteria of animal origin. The use of antimicrobial drugs may cause a transient increase in susceptibility to infection after exposure to a foodborne pathogen. This susceptibility may be separated into a so-called 'competitive effect' and a 'selective effect'; the selective effect offers a specific advantage for a resistant pathogen. 10, 11 In other words, drug-resistant gastrointestinal pathogens preferentially cause illness in persons receiving antimicrobial drugs for any medical condition. This issue has been studied in outbreak investigations and in case-control studies of sporadic infections, but little research has been carried out to investigate the long-term consequences of human antimicrobial drug use for acquiring resistant foodborne pathogens. Recently, Gradel et al., 8 found that Salmonella patients had an excess risk of being exposed to antimicrobials in the year before infection compared with their controls. Whereas this # The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org J Antimicrob Chemother 2010; 65: 1819 -1825 doi:10.1093/jac/dkq176 Advance Access publication 27 May 2010 observation could partly be ascribed to a long-term competitive effect of broad-spectrum antimicrobial use, the study also indicated that higher antimicrobial use might be a marker for frailty and therefore an indicator of patients who are more susceptible to becoming infected with, or are more likely to be diagnosed with, Salmonella. The study did not have sufficient statistical power to address whether a history of consumption of antimicrobial drugs conferred an excess risk of getting infected with drug-resistant Salmonella.
In the present nationwide registry-based study, we analysed the association between pre-infection exposure to antimicrobial drugs and laboratory-confirmed Salmonella infection. Due to the size of the study, we were able to address the role of drug resistance, and determine the long-term consequences of a history of antimicrobial use by different groups of antimicrobials. We were, on this basis, able to consider three different selective effects for acquiring resistance: the selective effect; the competitive effect; and the probable effect of selection bias or frailty.
Materials and methods

Registers
During the study period, from 1997 to 2005, all cases of Salmonella infection confirmed by faecal culture or by a culture from a normally sterile site were reported to Statens Serum Institut and data entered into the National Registry for Enteric Pathogens. 12, 13 Susceptibility testing was performed on a sample of submitted strains by the Unit of Gastrointestinal Infections of Statens Serum Institut.
14 For surveillance purposes, all isolates of serotype Typhimurium were targeted for susceptibility testing whereas we examined a random sample of other serotypes (with Enteritidis as the most common). In total, 46% (10408 samples) of the strains included in the present study were susceptibility tested; ranging from 97% of the Salmonella Typhimurium strains to 29% of other serotypes (Table 1 ). The data were entered into these databases including a unique personal identification number used in the Danish Civil Registry System. The personal identification number enables linkage between the different surveillance and public health databases. 15 Information on county and municipality can be directly deduced from the Civil Registry System.
To obtain data on exposure to antimicrobial drugs prior to the Salmonella infection, we used the National Prescription Database. This database contains information on all prescriptions provided by general practitioners, and is collected at local pharmacies. Data were entered using the Civil Registry System number and included the generic name of the drug, the ATC code, dosage, price and date of issue.
To control for the confounding effect of education and socioeconomic status, we obtained data on schooling and income from the Integrated Database on Labour Market Research. 16 
Case patients and controls
Patients enrolled in our study were all culture-confirmed cases with Salmonella with receipt of culture or specimen between 1 January 1997 and 31 December 2005. For each case we selected 10 control persons who were alive at the day of receipt of the strain and matched for sex, age and county of residence.
Data from the National Prescription Database was available from 1 January 1995 until 31 December 2005.
Data analyses
We defined the index date as the date 21 days before the date the sample was entered in the National Registry for Enteric Pathogens. These 21 days are composed of two time intervals; we assumed that there is an average delay of 7 days between the visit to the doctor's office or admission to hospital and the date the sample is entered in the database. The other 14 days we consider being an 'acute phase' of infection. Drugs prescribed in this acute phase are likely to represent treatment of the Salmonella infection, in particular as early empirical treatment for diarrhoea, and therefore causes bias to the outcome: Koningstein et al. Figure 1 . Cubic spline plots of the OR of being exposed to broad-spectrum penicillins and fluoroquinolones 0-2 years before infection with Salmonella Typhimurium, Salmonella Enteritidis and other Salmonella, 1997 -2005 Denmark. The ORs are adjusted for sex, age, county of residence, population density, income and schooling.
protopathic bias. 17 For this reason, drugs taken in this time frame were excluded from our main analysis.
Odds ratios (ORs) for exposure to antimicrobial drugs before the index date were calculated in a conditional logistic regression model; Table 1 outlines the categorization of antimicrobial drugs and the number of susceptibility-tested cases. Further, a time-dependent OR for exposure to antimicrobials, in six different intervals before infection, was estimated as a function of time before onset of infection. In addition, we applied cubic splines 18 to obtain a smooth curve (Figure 1 ). The time frames were the 'acute phase' and 0 -2 weeks, 2-4 weeks, 1 -6 months, 6 -12 months and 1 -2 years before the index date. All estimated ORs were adjusted for rural/urban differences by population density (separated into five categories; .2000, 1001-2000, 351-1000, 26-350 and 1 -25 persons/km 2 ), schooling (primary school only or more than primary school) and income [income per household/number of adults in the household matched within 100 000 Danish Kroner ( US $18 000) intervals]. 13 Effect modification by age was determined by fitting an interaction term by three age groups (0-15 years, 15-64 years and ≥65 years). All analyses were performed using conditional logistic regression, with the PHREG procedure in SAS 9.1.3 for UNIX (SAS Institute, Cary, NC, USA) or SAS version 9.1 for Windows.
Results
In the study period, a total of 22 602 Salmonella cases were reported, including 4675 (20.7%) Salmonella Typhimurium, 12 151 (53.8%) Salmonella Enteritidis and 5776 (25.6%) other Salmonella serotypes (Table 1) . We matched a total of 214 325 controls to these patients. The median age for patients with infections of Salmonella Typhimurium, Salmonella Enteritidis and other Salmonella serotypes was 32, 38 and 31 years, respectively.
There was no difference in age and gender distribution among patients with a susceptibility-tested Salmonella strain compared with patients with strains that were not susceptibility tested. The numbers of resistant isolates were very low for some of the antimicrobials (e.g. no isolates of Salmonella Enteritidis were resistant to third-generation cephalosporins and no isolates belonging to the group of other serotypes were resistant to amphenicols; Table 1 ). Due to this limited number of observations, we excluded the following groups of antimicrobials from our analyses: amphenicols; aminoglycosides; third-generation cephalosporins; and the group named 'other antibacterials'. Either there were not enough prescriptions or the number of resistant isolates was inadequate for a meaningful analysis. Amphenicols have not been prescribed in Danish general practice since 1998, aminoglycosides and third-generation cephalosporins are mostly prescribed in hospitals and drugs that are prescribed in hospitals are not included in the National Prescription Database.
Outcome data
In the year prior to Salmonella diagnosis, patients more frequently had a history of antimicrobial drug use than population controls. This was observed independent of serotype and susceptibility pattern, and was found for all classes of drugs but with some variation in estimates (Table 2) . Data pertaining to susceptibility-tested strains only are given in Table 3 . For several drugs (fluoroquinolones, tetracyclines and broad-spectrum penicillins), there was an effect modification, i.e. resistant strains conferred a higher OR for salmonellosis than susceptible strains. The effect modification was statistically significant for fluoroquinolone-resistant Salmonella Typhimurium and Salmonella Enteritidis. The risk of being diagnosed with a fluoroquinolone-susceptible Salmonella Typhimurium after having taken a course of fluoroquinolones was 2.0 times higher for patients than for controls, whereas the risk of having a fluoroquinolone-resistant Salmonella Typhimurium was 7.2 (2.0×3.6) times higher for patients than for controls. The logistic regression model is multiplicative, and the product in the bracket is the main effect (OR 2.0 for susceptible strains) multiplied by the interaction term (OR 3.6 for the tested strain being resistant to the antimicrobial taken). Following the same argument, for Salmonella Enteritidis, the OR was 1.7 for a susceptible strain whereas it was 4.5 (1.7×2.7) for acquiring a resistant strain.
We determined the OR for being diagnosed with Salmonella after exposure to one of the groups of antimicrobials in different time frames before infection. The outcomes of this analysis for fluoroquinolones and broad-spectrum penicillins are given in Figure 1 . This graph shows the OR, on a log-scale, plotted against the time since latest antimicrobial exposure before infection with Salmonella, in cubic splines. In general the highest excess risk was found in a time window up to 1 month before diagnosis, and levelled out and became relatively stable 24 -6 months before diagnosis.
Sulphonamides and trimethoprim were also associated with a time-dependent excess risk of being diagnosed in particular for other serotypes than Salmonella Enteritidis and Salmonella Typhimurium. The ORs were 2.14 (95% CI: 1.43 -3.23) for 0-2 weeks, 1.17 (95% CI: 0.74 -1.87) for 2 -4 weeks, 1.23 (95% CI): 1.01-1.50) for 1 -6 months, 1.27 (95% CI: 1.06-1.53) for 6 -12 months and 1.40 (95% CI: 1.21-1.62) for 1 -2 years before infection.
We also investigated the effect of age on the outcomes, but we did not find any significant effect modification.
Discussion
A considerable body of research has addressed the link between antimicrobial use for food animals and the selection of antimicrobial-resistant pathogens, such as zoonotic Salmonella, and the subsequent risk of humans acquiring such a pathogen. 7,19 -23 However, it is also known that human consumption of antimicrobial drugs is of importance. During a large outbreak of Salmonella Typhimurium in pasteurized milk in the USA in 1984, Ryan et al. 24 found that in the month before onset of illness, use of antimicrobials to which the organism was resistant increased the risk of a symptomatic infection by .5-fold. The ORs are adjusted for sex, age, county of residence, population density, income and schooling.
a Cases that were exposed to antimicrobials 1 year before infection (and were infected with a strain that was resistant to the drug previously taken).
b Statistically this was fitted as an interaction term, the total relative risk for infection with a drug-resistant Salmonella that is resistant to the drug previously taken can be estimated as the product of the two ORs.
Salmonella resistance and human antimicrobial exposure At least two mechanisms may explain how antimicrobial drug use increases the risk of infection with resistant Salmonella. First, by depleting the normal gut flora and thus making the person susceptible to a smaller dose of ingested Salmonella. This mechanism has been described as the 'competitive effect', which is independent of the susceptibility pattern. 10, 11 Secondly, by giving a selective advantage to resistant Salmonella strains already colonizing the gut when the antimicrobial is taken. In the study by Ryan et al., 24 antimicrobial use lowered the dose of Salmonella needed to cause disease. The usual number of cups of milk drunk was less for ill persons who had taken antimicrobial in the month before illness than for ill persons who had not taken antimicrobials (2.4 versus 3.6 cups). This can be described as a 'selective effect', i.e. a specific advantage for the resistant pathogen. 10, 11 To our knowledge, the present study represents the first to investigate the long-term effects of antimicrobial drug exposure and, at the same time, distinguishes between these two mechanisms. The selective effect is a direct consequence of exposure to antimicrobial-resistant bacteria, in this case Salmonella, which has led to asymptomatic colonization. By taking a course of antimicrobials the balance of the gut flora will be disrupted, giving way to the antimicrobial-resistant bacteria to proliferate and cause clinical infection. We visualized this effect by calculating the OR that a patient was infected with a Salmonella strain that was resistant to the antimicrobial that was taken up to 1 year prior to the index date, of which the results are shown in Table 3 . The premise of our model is that the selective effect is a multiplication of the ORs given in this table: not only should the patient be exposed to the antimicrobial, the infective strain has to be resistant to the antimicrobial exposed.
For the overall effect of being exposed to a course of antimicrobial before infection, we have taken all Salmonella cases into account, whether they were susceptibility tested or not. We examined whether cases or controls were more likely to have been exposed to a course of antimicrobials previous to the index date of the case. Our results indicate that a history of antimicrobial drug use may confer an increased risk of being diagnosed with Salmonella; this risk is present up to at least 1 year after treatment. The effect may depend on several factors including the spectrum of the antimicrobial, the antibacterial effect of its metabolites and its pharmacokinetics.
Broad-spectrum penicillins, sulphonamides and trimethoprim are excreted mainly via the urine, and therefore have a lesser impact on the gut flora. 25, 26 This is also the case for most fluoroquinolones, but nevertheless, a significant part of this group of drugs is excreted in the bile. Also, some of the active metabolites of fluoroquinolones are excreted via the biliary route. This implies that fluoroquinolones and their metabolites have an impact on the gut flora by passing through the gastrointestinal tract, which may explain why the most consistent results were obtained for this drug. 27 Tetracyclines are excreted via both the biliary and the urinary pathways. This drug also reaches fairly high concentrations in the gastrointestinal tract in its unchanged form. 28 The effect seen in the first half year before infection, in Figure 1 , is a combination of the 'competitive effect', the 'selective effect' and the effect of treatment (protopathic bias). The effect of treatment can be seen if a patient had an antimicrobial prescription for diarrhoeal symptoms before the actual stool sample was taken. To account for the bias caused by the effect of treatment we introduced an index date, which excluded the 'acute phase' of exposure and an extra week that we estimated it takes for a sample to show up in the database. In Figure 1 , the effect seen half a year before infection is that the OR for being diagnosed with Salmonella increases after exposure to a course of antimicrobials in all, except for exposure to broadspectrum penicillins in Salmonella Enteritidis. We are not sure of the explanation of this effect: the half-lives of these drugs are very short (30 -80 min), so it is not caused by the physical presence of the drug itself, and if that were the case, the effect should have been the same for Salmonella Typhimurium and Salmonella Enteritidis equally. The effect seen might be explained by the low percentage of resistance to this group of antimicrobials in Salmonella Enteritidis ( 3%-6%), which is much higher in Salmonella Typhimurium ( 44% -56%).
14 The effect of taking a course of antibiotics 6 months to 2 years before infection can in part be ascribed to 'selection bias' (i.e. the effect that some people are more likely to be tested than other people). A history of drug use may also be an indicator of increased use of healthcare, and thus a marker of frailty, and therefore might contribute to this effect. Furthermore, a Salmonella carrier may develop diarrhoea due to the non-specific effect of the antibiotic and may get sampled on this basis. However, it cannot be completely ruled out that some antimicrobial drugs may have a long-term effect on the gut flora and thus render the patients more susceptible to salmonellosis.
Our study is subject to a number of limitations. One of the limitations lies within the study design, because it was an observational study and selection bias may be of importance as discussed above.
Some of the antimicrobials are mainly used in hospital settings, and these data are not included in the Danish prescription database. We can only speculate that the impact of antimicrobials on the occurrence of antimicrobial resistance would have been higher if we could also include these data. In Denmark, 90% of defined daily dosage of antibacterials is prescribed in the primary healthcare sector. 14 We did not adjust for co-morbidity in this study, but in a similar study, performed by Gradel et al., 8 this was taken into account and it did not affect the outcomes markedly. Therefore it is not likely that co-morbidity is an interaction factor in our study either.
To sum up, the use of fluoroquinolones, broad-spectrum penicillins, sulphonamides, trimethoprim and tetracyclines, up to 1 year before infection, was associated with a higher risk of Salmonella infection. In addition, patients who were exposed to fluoroquinolones had a significantly higher risk of contracting a Salmonella infection that was resistant to the antimicrobial taken, and a similar tendency was found for other classes of antimicrobial drugs.
Our data suggest that with an increasing number of antimicrobial prescriptions, the number of clinical infections with drug-resistant non-typhoid Salmonella is also likely to rise. 
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